These two injections are expected to be approved in the near future and will be the first to pass a consistent evaluation.

Text . . . On October 9th, PharmaGo, a pharmaceutical Rubik's Cube, showed that two applications for the listing of injections submitted under category 3 had entered the "in-approval" stage and were expected to be formally approved in the near future and treated as if they had passed a consistent evaluation, respectively, for injections of Lizhu Pharmaceuticals with danqulin sodium and Osaikang's injections with right rezos.
sodium injection with danqulin sodium is mainly used clinically to treat malignant hyperthermal fever.
hyperthermal fever is a hereditary myopathy characterized by high metabolism, which is a rare disease.
only 2 enterprises in China currently produce and sell danqulin sodium, dosage form for capsules.
has not yet been approved by domestic manufacturers, Lizhu Pharmaceuticals in February 2019 submitted an application for the drug to market, in April of the same year according to "rare diseases" into the priority review process.
injection with right rezosheng injection with right rezosen clinically mainly used for chemotherapy caused by cardiac toxicity, the domestic only one enterprise Osaikang production and sale of the drug.
May 2019, Osaikang resubmits its application for the listing of injection-based right rezoso, which, if approved, will be treated as a consistent evaluation.
.